Back to Mesothelioma News
Back to Mesothelioma News Center
Validation Data Shows Rosettas Array-Based CUP Test Outperforms PCR-based Predecessor
June 29, 2011Back to Mesothelioma News Center
Post-marketing validation of Rosetta Genomics' miRview Mets 2 has shown that the array-based test exhibited 88 percent concordance with clinical presentation and pathology on a set of cancer-of-unknown-primary samples, exceeding the accuracy of its predecessor PCR-based assay, miRview Mets.
Read the full story: Validation Data Shows Rosettas Array-Based CUP Test Outperforms PCR-based Predecessor
Mesothelioma
Lawsuit Evaluation
Lawsuit Evaluation
